

## Furoscix® (furosemide) – Expanded indication

- On March 7, 2025, <u>scPharmaceuticals announced</u> the FDA approval of <u>Furoscix (furosemide)</u>, for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.
  - Furoscix was previously approved for the treatment of congestion due to fluid overload in adults with chronic heart failure. This approval expands the use of Furoscix to include patients with CKD.
- The single-use, On-body Infusor with prefilled cartridge is pre-programmed to deliver 30 mg of Furoscix subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours.
  - Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical.
  - Furoscix is intended for use in a setting where the patient can limit their activity for the duration of administration.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.